Financial Data and Key Metrics Changes - The company reported a 27% increase in revenue to $14.5 million for Q4 2025, with full-year revenue also growing 27% to $52.2 million compared to 2024 [4][18] - Gross profit for Q4 was $11.1 million, up from $8.5 million in the prior year, increasing gross margin to 76% [19] - Net income for Q4 was $2.9 million, compared to $1.5 million in the same period of 2024, with full-year net income of approximately $7.6 million compared to $2.9 million in 2024 [23] Business Line Data and Key Metrics Changes - A total of 95 Deep TMS systems were shipped during Q4, bringing the installed base to approximately 1,700 systems, a 26% increase year-over-year [4][18] - The book-to-bill ratio improved to 1.4x from 1.2x in the previous quarter, indicating strong demand [5] Market Data and Key Metrics Changes - Remaining performance obligations reached $70 million, representing a 43% growth from $49 million a year ago, reflecting strong demand and long-term commitments [5][24] - The company estimates it has penetrated less than 10% of the market for Deep TMS, indicating significant growth potential [7] Company Strategy and Development Direction - The company is focusing on expanding reimbursement coverage with payers across the U.S. to increase market share [8] - A strategic initiative is in place to secure minority equity investments in high-performing mental health providers, which is expected to facilitate faster access to interventional psychiatry modalities [14][15] - The company aims to develop a portfolio of data-driven technology-enabled neuromodulation solutions to serve more patients and settings [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in the business and expects revenue in the range of $66 million to $68 million for 2026, representing a year-over-year growth rate of 27%-30% [24][25] - The company anticipates adjusted EBITDA of $12 million to $14 million for 2026, indicating expected growth of 86%-100% over 2025 [25] Other Important Information - The FDA granted label expansion for the Deep TMS system to treat adolescents aged 15 to 21 suffering from major depressive disorder, expanding the addressable patient population [9] - The company received a $2.5 million NIH grant for a study on Deep TMS for alcohol use disorder, highlighting ongoing clinical research efforts [12][13] Q&A Session Summary Question: Can you give us a better sense of the Q4 placements as far as units sold, units leased, and also any color regarding OCD placements? - Management reported that 95 systems were shipped during Q4, with more than 50% including H7 coils [26] Question: Can you talk about the Deep TMS 360 trial? - The trial is designed for addiction and neurology markets, with 10 centers actively recruiting patients for alcohol use disorder and three centers for Alzheimer's disease [28][29] Question: Was there any pricing change in 2025 or anticipated for 2026? - Management does not anticipate a decrease in average selling price and aims to optimize pricing based on the value provided [31]

Financial Data and Key Metrics Changes - In Q4 2025, the company delivered 780 homes, generating $260 million in revenue, a 9% decrease from the previous year [11] - The home closing gross margin was 19.9%, down from 25.5% in Q4 2024, while adjusted gross margin was 21% [11][14] - For the full year 2025, the company delivered 2,908 homes, a 1% increase over 2024, with revenue of $971 million, essentially flat compared to the prior year [13][14] - Net income for Q4 was $17 million, with adjusted net income of $12.8 million, down from $22.7 million in the same period last year [12][13] Business Line Data and Key Metrics Changes - The company generated 532 net new orders in Q4, with an average order price of $333,000, reflecting a 3% increase in net new home orders for the year [15] - The average sales price for homes was $334,000, down from $340,000 in 2024 [13][14] - The company ended the year with 512 homes in backlog, valued at approximately $173 million [15] Market Data and Key Metrics Changes - The company reported a 14% increase in total controlled lots to approximately 22,300 lots, primarily through option contracts [16] - The active community count increased by 28% to 100 communities compared to 78 communities at the end of 2024 [15] Company Strategy and Development Direction - The company aims to maintain discipline through the housing cycle, focusing on operational efficiency and market share growth [10][18] - The long-term strategy includes building affordable homes in markets with strong population growth and job creation [9] - The company is committed to a land-light strategy, allowing flexibility while expanding in attractive southern markets [16] Management's Comments on Operating Environment and Future Outlook - Management noted that the housing market has been in a recessionary environment for about 18 months, driven by affordability pressures and higher mortgage rates [19] - The macroeconomic environment remains uncertain, with mixed signals from recent economic data and geopolitical developments [20] - The company expects closings in Q1 2026 to be between 575 and 625 homes, with average sales prices between $330,000 and $335,000 [21] Other Important Information - The company has a conservative balance sheet, ending the year with $12.7 million in cash and a debt to book capitalization ratio of 9% [16] - Management emphasized the importance of maintaining sales pace and operational efficiency to protect the production engine [18] Q&A Session Summary Question: Sales pace and pricing trends in Q1 - Management noted that sales pace followed traditional seasonal patterns, with an uptick in February and early March [24][26] Question: Strengths and weaknesses across major markets - Management indicated similarities in market performance, with new markets expected to perform well once models are open [28] Question: Incentives and margin guidance for Q1 - Management confirmed that incentives were leaned into in Q4 to maintain sales pace, with a projected sequential decrease in gross margins for Q1 [34][36] Question: SG&A expenses and unusual items - Management explained that SG&A expenses were impacted by new divisions not yet fully operational, leading to higher costs [42] Question: Land cost trends and expectations for 2026 - Management indicated that while land costs are expected to increase slightly, there are signs of a reset in pricing for new deals [53]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, representing a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA was $42 million, up 23% year-over-year from $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in both ex-U.S. markets and royalty income from Takeda [10] - Revenues from Cytogam declined due to increased usage of antivirals, with ongoing efforts to demonstrate its advantages through a new clinical study [11][12] Market Data and Key Metrics Changes - The company secured a $10 million-$14 million extension of an existing tender from Canadian Blood Services for various products, ensuring ongoing sales in Canada from Q2 2026 to Q1 2028 [17] - The company anticipates growth in its distribution segment through the launch of additional biosimilars in Israeli markets and expansion into the MENA region [9][14] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio, including investment in FDA-approved specialty plasma-derived products and biosimilars [9] - Plans to ramp up plasma collection at new centers in Houston and San Antonio, with expected annual revenues of $8 million-$10 million per center at full capacity [15] - The company is pursuing new business development and M&A opportunities to enhance its product portfolio and generate synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial performance, despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 annual guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing growth from 2025 results [8] - Management emphasized the importance of Cytogam in organ transplant protection and the potential for increased usage following clinical studies [25] Other Important Information - A dividend of $0.25 per share was declared, totaling approximately $14.4 million, reinforcing confidence in business prospects [6][7] - The company plans to continue investing in growth while maintaining dividend payments [26] Q&A Session Summary Question: CMV market and Cytogam usage - Management noted no changes in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [23][24] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [26] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from plasma collection to start impacting gross profit in 2027 and beyond [27] Question: Plasma collection center ramp-up - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing for new biosimilars launch - New biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment timing - The entire dividend will be paid in the second quarter [39]

Financial Data and Key Metrics Changes - Consolidated fourth quarter 2025 revenue was $154.8 million, down from $163.3 million in the prior year, primarily due to softening customer demand [7] - Adjusted EBITDA for the fourth quarter was $2.3 million, compared to $0.9 million in the prior year, with adjusted EBITDA margins increasing to 1.5% from 0.6% [7][8] - Full year consolidated revenue was $649 million, down from $723.4 million in the prior year, with adjusted EBITDA at $17.8 million, down from $23.2 million [9][10] - Free cash flow for the full year was $33.7 million, up $21.5 million from last year, enabling a reduction in net debt by over $35 million [5][11] Business Line Data and Key Metrics Changes - Global Seating segment revenues decreased by 5.6% to $70.7 million in the fourth quarter, but adjusted operating income increased to $1.8 million [12] - Global Electrical Systems segment revenues increased by 12.7% to $49.7 million in the fourth quarter, with adjusted operating income rising to $0.9 million [13][14] - Trim Systems and Components revenues decreased by 22.5% to $34.4 million in the fourth quarter, resulting in an adjusted operating loss of $1.4 million [16][17] Market Data and Key Metrics Changes - The North American Class 8 truck market is experiencing a challenging demand environment, with a forecasted 4% increase in year-over-year volumes for 2026 [18] - The construction market is expected to grow in the low single-digit percentage range, driven by lower interest rates and fiscal stimulus initiatives [18] Company Strategy and Development Direction - The company is focusing on operational efficiency improvements and has announced a new contract with Zoox for autonomous vehicle components, indicating a strategic shift towards electric and autonomous vehicle markets [19][20] - The company aims to grow its Global Electrical Systems segment by more than 10% in 2026, supported by new business wins and increased capacity utilization [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about end market recovery and expects improved financial performance in 2026, with guidance for net sales between $660 million and $700 million [21][22] - The company anticipates generating positive free cash flow in 2026, which will be used to continue paying down debt and improving net leverage [21][22] Other Important Information - The company achieved a net leverage ratio of 4.1 times at the end of 2025, down from 4.7 times at the end of 2024 [10] - Interest expense for the fourth quarter was $4.2 million, up from $2.2 million in the prior year, driven by higher interest rates [8] Q&A Session Summary Question: Can you provide more color on the two key programs that started ramping in the third quarter? - Management confirmed that both programs are progressing as planned, with the Zoox program on track for volume production by the latter part of the second quarter [26][27] Question: What is the outlook for the aftermarket business? - The aftermarket business is expected to grow, driven by improved operational efficiencies and promotional initiatives [32][36] Question: What are the assumptions behind the guidance range for Adjusted EBITDA? - The guidance range reflects current macroeconomic trends and the anticipated recovery in Class 8 truck production, with expectations for significant drop-through of incremental top line [81][82]

Financial Data and Key Metrics Changes - In Q4 FY26, total revenue increased by 9% year-over-year to $220.6 million, while subscription revenue grew by 6% to $193.4 million [4][14] - Non-GAAP operating income for Q4 was $37.7 million, representing a 17% non-GAAP operating margin [4][17] - For the full year FY26, total revenue was $857.2 million, up 8% year-over-year, with subscription revenue of $756.3 million, up 5% [20][21] - Non-GAAP operating income for FY26 was $146.2 million, equating to a non-GAAP net income per diluted share of $0.49 [20][21] Business Line Data and Key Metrics Changes - Professional services revenue in Q4 was $27.1 million, up 29% year-over-year, driven by large-scale rollouts [14][20] - The subscription revenue base net dollar expansion rate in Q4 was 103%, with a net dollar expansion for the $1 million customer cohort at 115% [15][16] - The average revenue per customer in the $1 million cohort is now above $3 million [15] Market Data and Key Metrics Changes - ARR from generative AI-native Sprinklr Service SKUs grew by 50% year-over-year, indicating strong demand for AI capabilities [7] - The company operates in 12 regions, with the Americas contributing approximately 50-55% of revenue, Europe around 35%, and Asia-Pacific about 10% [38] Company Strategy and Development Direction - The company is in the second phase of its transformation, focusing on embedding changes made in FY26 to build a stronger foundation for scale and efficiency [5][12] - Key innovation priorities for FY27 include unified customer intelligence, enterprise-wide automation, AI-driven marketing, and next-generation AI insights [8] - The company aims to solidify its baseline and contribution from top-tier enterprise customers through its "bear hug" strategy [15][16] Management's Comments on Operating Environment and Future Outlook - Management noted that while churn was higher than preferred in FY26, renewal rates improved in Q4 and are expected to continue improving in Q1 and Q2 of FY27 [5][12] - The macro environment remains fluid, particularly due to geopolitical events, but the company is focused on maintaining discipline and positioning for growth [12][13] - Management expressed confidence in the strategy and commitment to delivering durable growth and long-term shareholder value [12][13] Other Important Information - The board has authorized a new $200 million share buyback program, reflecting confidence in the company's strategy and balance sheet [18] - The company generated $15.9 million in free cash flow in Q4 and $142 million for the year, with a strong balance sheet of $502.5 million in cash and no debt [17][18] Q&A Session Summary Question: Is the margin outlook conservative? - Management emphasized a balanced approach to investments while ensuring long-term growth and addressing technical debt [30][31] Question: What is the revenue breakdown between international and U.S. markets? - The Middle East is a healthy region for the company, contributing to a good pipeline, with the Americas being the largest market [36][38] Question: Will elevated churn continue in FY27? - Management expects renewal rates to improve, indicating a positive trend in customer retention [44][45] Question: What are the plans for increasing margins? - The company is focused on revenue mix, operational efficiency, and investing in AI solutions to support margin expansion [47][49] Question: What signals the transition to the acceleration phase? - Management highlighted the importance of improving renewal rates, customer sentiment, and operational efficiency as indicators for moving to the next phase [87][89]

Financial Data and Key Metrics Changes - In Q4 2025, the company delivered 780 homes, generating $260 million in revenue, a 9% decrease from the previous year [10] - Home closing gross margin was 19.9%, down from 25.5% in Q4 2024 [10] - Net income for Q4 was $17 million, or $0.39 per diluted share, compared to $30 million in the prior year [11] - For the full year 2025, the company delivered 2,908 homes, a 1% increase over 2024, with revenue of $971 million, essentially flat year-over-year [12] - Adjusted net income for Q4 was $12.8 million, down from $22.7 million in the same period last year [12] Business Line Data and Key Metrics Changes - The company generated 532 net new orders in Q4, reflecting a challenging sales environment [5] - Average sales price for homes was $334,000, down from $340,000 in 2024 [12] - SG&A expense for Q4 was $36 million, approximately 13.8% of revenue, compared to 14.9% in Q4 2024 [11] Market Data and Key Metrics Changes - The company ended the year with 512 homes in backlog, with an average sales price of $337,000, representing a backlog value of approximately $173 million [15] - Total controlled lots increased by 14% to approximately 22,300 lots, primarily through option contracts [16] Company Strategy and Development Direction - The company aims to grow volume and gain market share through targeted investments and a disciplined approach to home building [7] - The focus remains on building affordable homes in markets with strong population growth and job creation [8] - The company maintains a conservative balance sheet and prioritizes operational discipline to position itself for long-term success [9] Management's Comments on Operating Environment and Future Outlook - Management noted that the housing market has been in a recessionary environment for about 18 months, driven by affordability pressures and higher mortgage rates [19] - The macroeconomic environment remains uncertain, with mixed signals from recent economic data [20] - The company is optimistic about the spring selling season but acknowledges that demand remains inconsistent [6] Other Important Information - The company plans to repurchase shares when market conditions allow, while continuing to prioritize investments in land and community growth [20] - For Q1 2026, the company expects closings between 575 and 625 homes, with average sales prices between $330,000 and $335,000 [21] Q&A Session Summary Question: Can you provide insights on sales pace, pricing, and incentives trends in Q1? - Management indicated that sales pace followed traditional seasonal patterns, with an uptick in February and early March [24][26] Question: Are there any trends in strengths and weaknesses across major markets? - Management noted similarities in market pacing and expressed hope for new markets once models are open [28] Question: What is driving the decision to lean back into incentives? - Management explained that they are monitoring traffic and sales on a community basis, aiming to balance pace and margin [34] Question: How does the spec count look heading into Q1 2026? - Management stated that specs are running about half of current inventory, with a focus on pre-sold homes to maximize value [64] Question: What is the strategy around land purchases? - The company prefers finished lot takedowns and is seeing softening opportunities in better locations [68]

Financial Data and Key Metrics Changes - Company reported a 27% increase in revenue to $14.5 million for Q4 2025, with full-year revenue also growing 27% to $52.2 million compared to 2024 [4][17] - Gross profit for Q4 was $11.1 million, up from $8.5 million in the prior year, with gross margin increasing to 76% [18] - Operating income for Q4 was approximately $1.9 million, a significant increase from $0.4 million in the same period last year [21] - Net income for Q4 was $2.9 million, compared to $1.5 million in Q4 2024, with full-year net income of approximately $7.6 million compared to $2.9 million in 2024 [22] Business Line Data and Key Metrics Changes - 95 Deep TMS systems were shipped in Q4, bringing the total installed base to approximately 1,700 systems, a 26% increase year-over-year [4][17] - The book-to-bill ratio improved to 1.4x from 1.2x in the previous quarter, indicating strong demand [5] - Remaining performance obligation reached $70 million, representing a 43% growth from $49 million a year ago [5][22] Market Data and Key Metrics Changes - Company estimates it has penetrated less than 10% of the market for Deep TMS, indicating significant growth potential [6] - The FDA granted label expansion for Deep TMS to treat adolescents aged 15 to 21 with major depressive disorder, expanding the addressable patient population [8] Company Strategy and Development Direction - Company is focusing on expanding reimbursement coverage with payers across the U.S. to increase market share [7] - A strategic initiative is in place to secure minority equity investments in high-performing mental health providers, which is expected to facilitate growth and access to interventional psychiatry [13][14] - Long-term vision includes developing a portfolio of data-driven technology-enabled neuromodulation solutions to serve more patients [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in the business and expects revenue for 2026 to be in the range of $66 million to $68 million, representing a year-over-year growth rate of 27%-30% [23] - The company anticipates adjusted EBITDA of $12 million to $14 million for 2026, indicating expected growth of 86%-100% over 2025 [24] Other Important Information - Company maintained a strong cash position with $68 million in cash and cash equivalents as of December 31, 2025, supporting growth initiatives [22] - The SWIFT Deep TMS protocol is expected to significantly improve patient access and treatment efficiency, reducing the number of required office visits by 70% [10][11] Q&A Session Summary Question: Can you give us a little better sense of the fourth quarter placements as far as units sold, units leased, and also any color regarding OCD placements? - Company shipped 95 systems during Q4, with more than 50% including the H7 coils [25] Question: Can you talk about the Deep TMS 360 trial that's going on? - The TMS 360 is designed for addiction and neurology markets, with active recruitment for the alcohol use disorder trial in 10 centers across the U.S. [26][27] Question: As far as pricing, was there any pricing that you took in 2025 or would you anticipate any pricing for 2026? - Company does not anticipate any decrease in average selling price and aims to optimize pricing based on value provided [29] Question: What percentage of the $70 million obligations relates to commitments from existing strategic partners? - Each minority investment center is expected to deliver new backlog or booking of between $3-$5 million on a yearly basis [34] Question: Do you anticipate significant utilization of the SWIFT protocol for Deep TMS in conjunction with other therapies? - There is strong demand for TMS, and the SWIFT protocol is expected to be used in conjunction with other modalities, including psychedelics and medication management [39]

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Speaker8Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals fourth quarter and year-end 2025 corporate update conference call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may b ...

Financial Data and Key Metrics Changes - Consolidated fourth quarter 2025 revenue was $154.8 million, down from $163.3 million in the prior year, primarily due to softening customer demand [7][10] - Adjusted EBITDA for the fourth quarter was $2.3 million, compared to $0.9 million in the prior year, with adjusted EBITDA margins at 1.5%, up 90 basis points [8][9] - Net loss for the quarter was $6.4 million, or a loss of $0.19 per diluted share, compared to a net loss of $35 million, or a loss of $1.04 per diluted share in the prior year [9][10] - Free cash flow from continuing operations for the quarter was $8.7 million, compared to $0.8 million in the prior year [10] Business Line Data and Key Metrics Changes - Global Seating segment revenues decreased by 5.6% to $70.7 million, with adjusted operating income increasing to $1.8 million [13] - Global Electrical Systems segment revenues increased by 12.7% to $49.7 million, with adjusted operating income rising to $0.9 million [14] - Trim Systems and Components revenues decreased by 22.5% to $34.4 million, with an adjusted operating loss of $1.4 million [16] Market Data and Key Metrics Changes - The North American Class 8 truck market is experiencing a decline, impacting demand across several segments [4][16] - The construction market is expected to grow in the low single-digit percentage range, driven by lower interest rates and fiscal stimulus initiatives [18] Company Strategy and Development Direction - The company is focusing on operational efficiency improvements and has announced a new contract with Zoox for autonomous vehicle components, indicating a strategic shift towards electric and autonomous vehicle markets [5][19] - The company aims to grow its Global Electrical Systems segment by more than 10% in 2026, supported by new business wins [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about a 4% increase in Class 8 truck build volumes for 2026, with expectations of a rebound in 2028 [18] - The company anticipates a year of top-line growth with net sales guidance of $660 million to $700 million for 2026, reflecting nearly 5% growth over 2025 [21] Other Important Information - Free cash flow generation and debt paydown remain a focus for the company in 2026, with a target leverage ratio of 2x [21] - The company generated $33.7 million in free cash for the full year, up $21.5 million from the previous year [5][12] Q&A Session Summary Question: Can you provide more color on the two new key programs? - Management confirmed that both programs are ramping up as planned, with the Zoox program on track for volume production by the second quarter [25][26] Question: What is the outlook for the aftermarket business? - The aftermarket business is expected to grow, driven by improved operational efficiencies and promotional initiatives [32][36] Question: What are the assumptions behind the guidance range for Adjusted EBITDA? - The guidance range reflects the volatility in the Class 8 truck market and the expectation of improved operating leverage as volumes increase [81][84]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA for 2025 was $42 million, reflecting a 23% increase compared to $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million, or $0.35 per diluted share, a 40% increase from $14.5 million, or $0.25 per diluted share, in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in ex-U.S. markets and royalty income from Takeda [10] - Revenue from Cytogam declined due to increased usage of antivirals, but a comprehensive post-marketing research program is expected to support future growth [11][12] Market Data and Key Metrics Changes - The company anticipates growth in the distribution segment through the launch of additional biosimilars in Israeli markets and expansion into the MENA region [9][13] - The Canadian Blood Services awarded a $10 million-$14 million extension for the supply of various products, securing ongoing sales in the Canadian market [17] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio and investing in the commercialization of FDA-approved specialty plasma-derived products [9] - Plans to ramp up plasma collection at new centers, aiming for significant revenue generation from normal source plasma sales starting in 2026 [14] - The company is pursuing M&A opportunities to enrich its product portfolio and generate synergies with existing operations [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial performance, despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing growth from 2025 results [7][8] - Management emphasized the importance of Cytogam in organ transplant protection and the potential for increased utilization following ongoing clinical studies [24] Other Important Information - A dividend of $0.25 per share, totaling approximately $14.4 million, was declared, reinforcing confidence in business prospects and liquidity [6] - The company expects to launch two additional biosimilars in Israel in mid-2026, contributing to growth in the distribution business [13][32] Q&A Session Summary Question: Impact of antivirals on Cytogam market - Management noted no change in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [22][23] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [25] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from proprietary plasma collection to start impacting gross profit in 2027 and beyond [26] Question: Ramp-up of plasma collection centers - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing of biosimilars launch - Two additional biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment schedule - The entire dividend will be paid in the second quarter [40]